{"filing":{"accession_number":"0001178913-26-004609","cik":"0002022416","ticker":"SLXNW","company_name":"Silexion Therapeutics Corp","form":"8-K","filing_date":"2026-09-25","report_date":"2026-09-25","primary_document":"zk2636161.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326004609/zk2636161.htm"},"events":[{"id":35126,"run_id":32347,"accession_number":"0001178913-26-004609","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"Silexion received a formal notice from Nasdaq on September 25, 2026, that its ordinary shares have failed to maintain the minimum $1.00 bid price required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The Nasdaq hearings panel will consider whether to allow the company to remain listed on the Nasdaq Capital Market. This is a classic delisting risk disclosure under Item 3.01, materially threatening the company's continued exchange listing.","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-25","form":"8-K","submitted_at":null,"items":[{"id":39068,"accession_number":"0001178913-26-004609","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Silexion received a formal notice from Nasdaq on September 25, 2026, that its ordinary shares have failed to maintain the minimum $1.00 bid price required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The Nasdaq hearings panel will consider whether to allow the company to remain listed on the Nasdaq Capital Market. This is a classic delisting risk disclosure under Item 3.01, materially threatening the company's continued exchange listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T20:30:09.718328+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39068,"accession_number":"0001178913-26-004609","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"Silexion received a formal notice from Nasdaq on September 25, 2026, that its ordinary shares have failed to maintain the minimum $1.00 bid price required under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days. The Nasdaq hearings panel will consider whether to allow the company to remain listed on the Nasdaq Capital Market. This is a classic delisting risk disclosure under Item 3.01, materially threatening the company's continued exchange listing.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-25T20:30:09.718328+00:00","company_name":"Silexion Therapeutics Corp","ticker":"SLXNW","filing_date":"2026-09-25"}]}